Funds · 13F holdings

Enavate Sciences GP, LLC

13F holdings for Q2 2026 · New York, NY · filed August 14, 2026

Enavate Sciences GP, LLC reported $345M in 13F securities across 7 holdings for Q2 2026, in a Form 13F filed August 14, 2026. The largest positions were SION (31.6%), ZBIO (28.8%), IMNM (22.2%). Reported value fell 1.7% from the quarter before. It opened 0 new positions, added to 0, trimmed 1 and sold out of 0.

13F value Q2 2026
$345M
Holdings
7
Change vs prior quarter
-1.7%
Rank by 13F value
#4,854

Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.

Top holdings

StockValueWeightSharesChange in sharesMove
SION Sionna Therapeutics Inc.$109M31.6%2,478,0300%Unchanged
ZBIO Zenas BioPharma Inc.$99.5M28.8%3,919,1590%Unchanged
IMNM Immunome Inc.$76.6M22.2%3,613,7990%Unchanged
BBOT BridgeBio Oncology Therapeutics Inc.$20.0M5.8%2,626,9460%Unchanged
CMPX Compass Therapeutics Inc.$17.1M4.9%7,788,1500%Unchanged
UPB Upstream Bio Inc.$17.0M4.9%2,459,7030%Unchanged
CAMP CAMP4 Therapeutics Corporation$6.2M1.8%1,425,541-34.9%Trimmed

Share positions only, at the value reported for the end of Q2 2026. Weight is the share of $345M in share positions; options and bonds count in the 13F value but not here.

Biggest buys in Q2 2026

None this quarter.

Biggest sells in Q2 2026

  1. CAMP CAMP4 Therapeutics Corporation Trimmed-$3.3M

The change in shares since Q1 2026, adjusted for stock splits and priced at the Q2 2026 value per share. 0 new, 0 added, 1 trimmed, 0 sold out.

13F value by quarter

Q4 '24
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Q1 '26
Q2 '26
Reported 13F value: Q4 2024 $139M, Q1 2025 $133M, Q2 2025 $177M, Q3 2025 $328M, Q4 2025 $507M, Q1 2026 $352M, Q2 2026 $345M.

Schedule 13D and 13G filings by Enavate Sciences GP, LLC

Stakes above 5% of a company, filed within days rather than once a quarter.

Questions about Enavate Sciences GP, LLC

What does Enavate Sciences GP, LLC own?
In its Form 13F for Q2 2026, Enavate Sciences GP, LLC reported 7 holdings worth $345M. The five largest were SION, ZBIO, IMNM, BBOT, CMPX.
What did Enavate Sciences GP, LLC buy and sell in Q2 2026?
Enavate Sciences GP, LLC opened 0 new positions, added to 0, trimmed 1 and sold out of 0 compared with the quarter before.
When did Enavate Sciences GP, LLC file its latest 13F?
Form 13F is due 45 days after each quarter ends. The Q2 2026 report was due August 14, 2026 and was filed August 14, 2026.

From Form 13F filed by Enavate Sciences GP, LLC (SEC CIK 0001953107) for the quarter ended June 30, 2026, via the SEC's Form 13F data sets. Amendments that restate a report replace it; amendments that add holdings are included. View on SEC EDGAR · All funds